The Sanofi-Aventis Acquisition of Genzym...
Matos, Pedro, Aley...
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, Chong
F-1715 | Published October 22, 2014 | 16 pages Case
Collection: Darden School of Business
Product Details
This case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (CVR). Was a CVR the magical solution to bridging the valuation gap?
0
Get Ahead in Class
Clear, Complete, and Concise: Avoiding t...
Lipson, Marc L.
Business Valuation in Mergers and Acquis...
Schill, Michael J....
A Brief Introduction to Macroeconomics
Murphy, Daniel
Moral Theory, Frameworks, and the Langua...
Wicks, Andrew C.; ...
Three Empirical Methods for Calculating ...
Zhang, Zhihao; Whi...
The Basics of Multivariate Regressions i...
Batova, Tatiana
Advanced Tableau Tips and Tricks
Palomba, Anthony
Digital Marketing Metrics: Measuring Wha...
Venkatesan, Rajkum...
Disruption, Response, and Transformation...
Chen, Ming-Jer; Mc...
Using AI to Expand Your Leadership Commu...
Murray, Meghan
Understanding Organizational Culture: An...
Martin, Sean; Kemp...
A Brief Introduction to Managerial Accou...
Lynch, Luann J.
How to Prototype a Prototype
Chao, Raul O.
The Strategist’s Toolkit
Lenox, Michael; Ha...
Finance People
Schill, Michael J.